Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 1999

View Archived Issues

Pharming: Q4 and year-end results

Xoma: year-end 1998 highlights

Cell Therapeutics anticipates oncology milestones for 1999

Nesiritide improves symptoms, hemodynamics in both moderate and severe CHF

Results from brasofensine trial in Parkinson's disease released

Potential CNS effects of insulin in humans

Cypress Bioscience and Fresenius sign definitive agreement for Prosorba Column

Greater reductions in LDL cholesterol lead to fewer cardiac events

Transgene initiates second phase II trial with Vero-IL-2 in mesothelioma

Viable myocardium can be detected using SHU-563A for contrast enhancement

Bristol-Myers Squibb completes U.S. filing for Orzel, the first oral treatment for colon cancer

Dual vasopeptidase inhibition provides considerable therapeutic benefit in heart failure

Cor Therapeutics presents cromafiban, the first orally active once-daily gpIIb/IIIa antagonist

Health Canada approves Viagra

Results of phase II FROST study of lefradafiban presented at ACC

Astra presents results of first human trial of AR-C69931MX at ACC meeting

Improved non-nucleoside HIV-1 RT inhibitors in development at Boehringer Ingelheim

Heterocyclic factor Xa inhibitors disclosed by Zeneca

Inhibitors of metallo-beta-lactamases discovered at SmithKline Beecham

Novel neuraminidase inhibitors described by U. of Florida

Protein prenylation inhibitors under study at Pierre Fabre for use in cancer, etc.

Novel class of GABA-A receptor ligands for cognitive disorders from Merck

Eplerenone, a novel SARA from Searle, is effective in the treatment of heart failure

WHI-P154 enhances the response of mast cells in infections

Vertex initiates phase I clinical trial with VX-745

Resolution Pharmaceuticals initiates phase I/II study of lead oncology imaging product

Repligen to develop novel treatment for autism; clinical trials slated to begin this year

DDE-131, a potential treatment for mast cell-mediated hypersensitivity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...